Sign inJoin waitlistJoin the waitlist

Ajay Dhakal

Associate Professor - Department of Medicine, Hematology/Oncology · URochester Medicine

Credentials: · · ·

History

URochester Medicine
Present

Roswell Park Cancer Institute
2015–2018
Maimonides Medical Center
2013–2015
Maimonides Medical Center
2012–2013
Kathmandu Medical College Teaching Hospital
2009
Kathmandu Medical College
Until 2009

Research

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor…
Journal of Clinical Oncology · 2024 · 45 citations
Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
Review · Cancers · 2024 · Last of 9 authors · Corresponding · 40 citations
Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
Breast Cancer · 2020 · First of 13 authors · Corresponding · 37 citations

Ruth O’Regan
9 papers
Carla Falkson
7 papers
Huina Zhang
7 papers
Bradley Turner
6 papers
David Hicks
6 papers
Carey Anders
5 papers
Shipra Gandhi
5 papers
Anna Weiss
3 papers
Brian Finkelman
3 papers · 2 as a fellow
Kazuaki Takabe
3 papers
Mateusz Opyrchal
3 papers
Nimish Mohile
3 papers

Clinical trials

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
Principal investigator · Withdrawn · Phase 2
University of Rochester
2025–2027
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
Principal investigator · Recruiting · Phase 2
University of Rochester
2022–2027
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2029
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032